Theodore Alan Huizenga Ultragenyx Pharmaceutical Inc. (RARE) insider trading activity

Theodore Alan Huizenga is SVP, Chief Accounting Officer of Ultragenyx Pharmaceutical Inc.. Currently has a direct ownership of 50,450 shares of RARE, which is worth approximately $1.67 Million. The most recent transaction as insider was on Dec 21, 2022, when has been sold 2,031 shares (Common Stock) at a price of $43.96 per share, resulting in proceeds of $89,282. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 50.5K

0.41% 3M change

20.58% 12M change

Total Value Held $1.67 Million

Theodore Alan Huizenga Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 21 2022	SELL Open market or private sale	$89,282 $43.96 p/Share	2,031 Reduced 11.14%	16,197 Common Stock
Sep 01 2022	BUY Grant, award, or other acquisition	-	1,000 Added 5.24%	18,094 Common Stock
Apr 16 2022	SELL Open market or private sale	$11,161 $84.55 p/Share	132 Reduced 0.77%	16,914 Common Stock
Mar 01 2022	SELL Open market or private sale	$56,161 $66.62 p/Share	843 Reduced 5.99%	13,229 Common Stock
Mar 01 2022	BUY Grant, award, or other acquisition	-	3,710 Added 17.87%	17,046 Common Stock
Oct 14 2021	SELL Open market or private sale	$11,360 $81.14 p/Share	140 Reduced 0.99%	14,072 Common Stock
Sep 13 2021	SELL Bona fide gift	-	819 Reduced 5.45%	14,212 Common Stock

May 06 2021	SELL Open market or private sale	$16,141 $113.67 p/Share	142 Reduced 0.94%	15,031 Common Stock
Apr 16 2021	BUY Grant, award, or other acquisition	-	1,500 Added 9.07%	15,044 Common Stock
Mar 08 2021	SELL Open market or private sale	$362,070 $120.69 p/Share	3,000 Reduced 18.13%	13,544 Common Stock
Mar 01 2021	SELL Open market or private sale	$101,140 $138.17 p/Share	732 Reduced 4.24%	16,544 Common Stock
Mar 01 2021	BUY Grant, award, or other acquisition	-	1,560 Added 8.28%	17,276 Common Stock
Jan 07 2021	SELL Open market or private sale	$562,600 $140.65 p/Share	4,000 Reduced 20.29%	15,716 Common Stock
Jan 07 2021	BUY Exercise of conversion of derivative security	$84,000 $21.0 p/Share	4,000 Added 16.37%	20,436 Common Stock
Oct 14 2020	SELL Open market or private sale	$12,845 $87.98 p/Share	146 Reduced 0.88%	16,436 Common Stock

TAH

Theodore Alan Huizenga

SVP, Chief Accounting Officer

Novato, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RARE shares.

Notify only if

Value

Insider Trading

Get notified when an Ultragenyx Pharmaceutical Inc. insider buys or sells RARE shares.

Notify only if

Operation

Value

Type

News

Receive news related to Ultragenyx Pharmaceutical Inc.

Track Activities on RARE

Account